PIPE-307
Relapsing Remitting Multiple Sclerosis (RRMS)
Key Facts
About Contineum Therapeutics
Contineum Therapeutics leverages its expertise in neuro-immunology to develop next-generation therapies for complex diseases of the central nervous system and inflammatory conditions. The company's strategy centers on targeting specific receptor pathways implicated in disease progression, with its lead candidate, PIPE-307, in Phase 2 for multiple sclerosis and PIPE-791 in Phase 1 for idiopathic pulmonary fibrosis. Following its successful IPO in April 2024, Contineum is well-capitalized to advance its clinical pipeline and explore the therapeutic potential of its novel mechanisms of action.
View full company profileAbout Contineum Therapeutics
Contineum Therapeutics leverages its expertise in neuro-immunology to develop next-generation therapies for complex diseases of the central nervous system and inflammatory conditions. The company's strategy centers on targeting specific receptor pathways implicated in disease progression, with its lead candidate, PIPE-307, in Phase 2 for multiple sclerosis and PIPE-791 in Phase 1 for idiopathic pulmonary fibrosis. Following its successful IPO in April 2024, Contineum is well-capitalized to advance its clinical pipeline and explore the therapeutic potential of its novel mechanisms of action.
View full company profile